Latest research on Venlafaxine

Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006. [Wikipedia]

Latest findings

In addition, the long-term efficacy of Venlafaxine ER has been reported in several studies, including the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study (Montgomery ; Simon ; Keller ; Kornstein ). [source, 2016]
The antidepressant types were divided into three categories: i) selective serotonin reuptake inhibitors including Citalopram, esCitalopram, fluoxetine, Paroxetine, and Sertraline, ii) newer antidepressants such as Bupropion, Venlafaxine, and Mirtazapine, and iii) older anti-depressants such as Amitriptyline, Clomipramine, Imipramine, Milnacipran, Nortriptyline, tianeptine, and Trazodone. [source, 2016]
There are also a few studies that have demonstrated the effects of the SNRIs Levomilnacipran,42 Venlafaxine,11 and desVenlafaxine43,44,46 on several types of functional outcomes in patients with MDD. [source, 2016]
The anticonvulsants Pregabalin and Gabapentin, low-dose TCAs, SSNRIs Duloxetine and Venlafaxine, and topical Lidocaine showed efficacy for the management of NP and were recommended as first-line and second-line medications, respectively. [source, 2016]
The approved maximum daily dosage of Venlafaxine extended release (ER) is 225 mg in most countries. [source, 2016]
Venlafaxine was the first SNRI approved by the FDA in 1993 for the treatment of MDD in adults (Papakostas, 2009a) as an immediate-release (IR) formulation. [source, 2016]
Venlafaxine ER, an oral once-a-day formulation of Venlafaxine HCl (1-[2-(dimethylamino)-1-(4-methoxyphenyl) ethyl] cyclohexanol-HCl), has shown the same exposure as Venlafaxine IR formulation with a dosing of two or three times a day. [source, 2016]
The robust acute efficacy of Venlafaxine IR and ER has been established over placebo-controlled studies that involved both fixed-dose and flexible-dose regimens (fixed-dose regimens: Mendels ; Khan ; Rudolph , flexible-dose regimens: Cunningham, 1997; Thase, 1997; Rudolph and Feiger, 1999; Silverstone and Ravindran, 1999) at doses ranging from 75 to 375 mg/day. [source, 2016]
The present study is a randomized, placebo-controlled investigation of the benefits and risks of Venlafaxine treatment in Japanese patients with MDD. [source, 2016]
More specifically, the primary aim was to compare the antidepressant efficacy after 8 weeks of double-blinded treatment with a fixed dose of 75 mg/day of Venlafaxine ER, flexible doses of 75–225 mg/day of Venlafaxine ER, or placebo. [source, 2016]